Tuesday, November 28, 2017

Study using artificial intelligence to identify compounds that mimic the longevity effects of calorie restriction published in November 2017 issue of Aging Journal

GEROPROTECT™ Longevity A.I.™ From Life Extension® provides anti-aging extracts that targets the anti-aging pathways as calorie restriction mimetics found in the study.

A study published in the November 15, 2017 issue of the Aging Journal addressed the need to identify nutraceuticals—safe, naturally-occurring compounds—that mimic the anti-aging effects of calorie restriction, and revealed how these compounds were identified using artificial intelligence. 
Calorie restriction is associated with enhanced longevity. However, for many it is an impractical or impossible long-term strategy. Thus, the goal of this study was to identify compounds that activate the same anti-aging pathways as a calorie restriction mimetic.
The study, a collaboration between Insilico Medicine and Life Extension, applied gene expression data from the Library of Integrated Network-based Cellular Signatures (LINCS) L1000 dataset to map the gene- and pathway-level signatures of a calorie restriction mimetic and screened for matches among over 800 natural compounds. They then predicted the safety of each compound with an ensemble of deep neural network classifiers. 
Several complementary approaches were employed including conventional statistical methods, pathway scoring-based methods, and training of deep neural networks (DNN) for signature recognition. To evaluate potential adverse effects of top-scoring natural compounds, a set of deep learned predictors, trained on transcriptional response data, were utilized.
This study also revealed promising candidates for future experimental validation while demonstrating the applications of powerful screening methods for this and similar endeavors. Moreover, the scientific research opportunities that this presents are as endless as the contributions that a socially and economically active, secure and healthy aging population can bring to society.
Life Extension utilized the findings of this artificial intelligence empowered study to develop a novel dietary supplement called GEROPROTECTTM Longevity A.I. Longevity A.I, is an innovative combination of three natural nutrients, withaferin a, gamma-linolenic acid, and ginsenoside Rg3 from Asian ginseng, that mimic known metabolic regulators of the same anti-aging pathways targeted by calorie restriction mimetics, which have long been associated with increased life expectancy.
"GEROPROTECT™ Longevity A.I.™ is the only formation to combine three potential life-prolonging ingredients into a single supplement," said Andrew G. Swick, Ph.D., senior vice president, product development and scientific affairs at Fort Lauderdale, Fla.-based Life Extension. "This unique formulation based on proprietary artificial intelligence technology contains these geroprotector ingredients in concentrations several magnitudes higher than conventional dietary supplements. We suggest that this novel formulation should be a keystone product in all life extensionists' supplement regimens."
Insilico, a next-generation artificial intelligence company specializing in the application of deep learning proprietary technology for biomarker development and aging research, used pioneering high-performance computer simulations to probe of the effect of extracts on anti-aging pathways.  
The company is located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. Insilico utilizes advances in genomics, big-data analysis, and deep learning for developing products for various health related industries. 
"We researched thousands of natural compounds and their combinations using our proprietary deep-learning artificial intelligence technology to identify the optimal combination of ingredients that activate the same anti-aging pathways as a calorie restriction mimetic," said Alex Zhavoronkov, Ph.D. and chief executive officer of Insilico Medicine, Inc. "Without this technology our search to swiftly fight back against aging would have literally taken decades to determine and achieve."
Full text of the study can be found at http://www.aging-us.com/article/101319/text#fulltext.
For over 37 years, Life Extension has been a pioneer in funding and reporting the latest anti-aging research and integrative health support while offering superior-quality dietary supplements. Life Extension develops and manufactures more than 350 science-based formulations that set the standard for quality, purity, and potency. A trailblazer in the $37 billion U.S. dietary supplements industry, Life Extension has a long history of offering prescient health guidance to American consumers, often years ahead of the mainstream medical establishment. Life Extension is an organization dedicated to finding new scientific methods to enhance and expand the healthy human life span. It funds research programs aimed at developing new scientific breakthroughs and has donated more than $175 million to anti-aging studies.

Thursday, November 23, 2017

Chemistry.AI to analyze the brain activity of medicinal chemists for AI-powered drug discovery



Insilico announces a new crowd-sourced platform that will use EMOTIV's neuroscientific data collection and processing to perform the first Turing test for molecules generated using AI and to involve the medicinal chemists into AI-powered drug discovery

Wednesday, 22nd of November, 2017, Baltimore, MD, Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery announced the launch of the first phase of the Chemistry.AI program. Chemistry.AI is a crowd-sourced platform for analyzing the brain's response of medicinal chemists to the molecules developed using artificial intelligence technologies and other expert medicinal chemists. The neuroscientific response is evaluated by analyzing the brain activity of the medicinal chemists using a ubiquitous mobile electroencephalography (EEG) device called EPOC+ produced by EMOTIV. EPOC+ also provides data about head motion and certain facial expressions. EMOTIV, the world leader in consumer EEG offers brain sensors and cloud-computing solutions to scale the collection and processing of behavioral and brain data that will be used together with eye-tracking and video monitoring techniques in the current project.
"Using our mobile sensors and cloud computing solutions to better understand the brain activity of medicinal chemists, will provide unique insights on what distinguishes experts chemists from others, that no other methodology could", said Tan Le, CEO of EMOTIV (@tanttle)
"Medicinal chemists with several years of experience have the ability to distinguish the good molecules from the bad ones just by looking at their structure or its numerical properties and various scores. Depending on their prior experience with the various types of chemistry, e.g. kinase chemistry or GPCR chemistry and their background, their assessment is often biased. With Chemistry.AI we are hoping to achieve two major goals: capture the tacit knowledge possessed by medicinal chemists and put the output of the molecules generated using AI to the test by some of the best human scientists in a version of a Turing test", said Alex Zhavoronkov, PhD, the founder of Insilico Medicine, Inc. 
Medicinal chemistry is among one of the most important and intellectually-challenging professions on the planet. It takes decades of training and experience to learn the properties of the thousands of molecules and their effects on the biological systems, model organisms and diseases. Decisions made by the medicinal chemists affect the lives of billions of people and may result in the billions of dollars of gains or losses for the pharmaceutical companies.
Experienced medicinal chemists have the ability to accurately describe the properties and the possible effects of the molecule just by looking at its structure, as well as at the various numerical parameters.
They may favour certain molecular structures because of their experience with the hundreds of thousands of molecules they encountered previously and the emotional response to the molecule is usually biased and related to the molecules and the classes of molecules they are most familiar with.
Chemistry.AI will provide a platform for the medicinal chemists to look at the various classes of molecules and measure their brain activity and other physiological parameters during the exposure to the molecule.
###
For further information, images or interviews, please contact:
Contact: Qingsong Zhu, PhD 
zhu@pharma.ai
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Taiwan, Russia, and the UK sourced through hackathons and competitions.
The company utilizes advances in genomics, big-data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company is pursuing internal drug discovery programs in cancer, dermatological diseases, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging itself.
Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. http://www.insilico.com
About EMOTIV
EMOTIV is the leading mobile bioinformatics company, advancing understanding of the human brain using electroencephalography (EEG). Its mission is to empower individuals to understand their own brain and accelerate brain research globally. 
EMOTIV has developed unique machine learning algorithms that allow the user to track cognitive performance, detect facial expressions and control both virtual and physical objects via trained mental commands.
EMOTIV leads the field of mobile brain sensors in terms of innovation, technology and support from the scientific community. Its technology is currently being used in more than 110 countries by more than 80,000 individuals who own one of its brainwear. It has been validated and included in over 4,000 publications. EMOTIV believes in the power of the human brain and the ability to tap into its potential to open up new possibilities for improving performance, health, wellness and ultimately, prevent disease. https://www.emotiv.com/






Wednesday, November 15, 2017

Converging blockchain and next-generation AI technologies to accelerate biomedical research

Blockchain and AI researchers propose a new model to return the control over human life data to the patients and accelerate biomedical research
Wednesday, 15th of November, 2017, 10AM EST, Baltimore, MD, Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery announced the publication of a new peer-reviewed research paper titled" Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare" in Oncotarget. Insilico Medicine scientists specializing in deep learning collaborated with the scientists and developers from the Bitfury Group, the world's leading full service Blockchain technology company, specializes in securing the Blockchain and deploying cutting edge hardware and software solutions to governments, institutions, and corporations. In the paper the groups presented the first attempt to assess the value of time and the combination value of personal data in the context of an AI-mediated health data exchange on blockchain. 
"Most people do not understand what life data they have, how valuable and dangerous this data may be and do not have any control over how their life data is being used. The policy makers are trying to address this problem by introducing new regulations that make it expensive and difficult for the innovators to turn the human life data into life-saving products. In this paper we propose a blockchain-enabled solution to help people become aware of and take control over their data and profit from licensing the data to the innovators", said Polina Mamoshina, Sr. research scientist at Insilico Medicine. 
In this research paper scientists introduce new concepts to appraise and evaluate human life data, including the combination-, time- and relationship-value of the data and present a roadmap for a blockchain-enabled decentralized personal health data ecosystem to enable novel approaches for drug discovery, biomarker development, and preventative healthcare. A secure and transparent distributed personal data marketplace utilizing blockchain and deep learning technologies may be able to resolve the challenges faced by the regulators and return the control over personal data including medical records back to the individuals.
"We are enthusiastic that blockchain technology can help solve one of the major problems in modern healthcare - patient data management. We are even more excited that Insilico is building this solution on our open-source Blockchain framework, Exonum. An Exonum-based Blockchain provides security, transparency and reliability, which will significantly improve overall efficiency and patient satisfaction as well as provide an avenue for easier auditing. We look forward to sharing our progress", said George Givishvili, Chief Marketing Officer of Bitfury company.
Blockchain technology enables the creation of a distributed and secure ledger of personal data, where patients are in control, own their data, and monitoring of access privileges and understanding of who looked at the data. Most importantly, blockchain technology allows for the creation of a data-driven marketplace, where patients can earn tangible rewards for making their data available to the application development community, pharmaceutical and consumer companies, and research institutions and generating new data through regular and comprehensive tests and checkups. Presently, only a few patients worldwide have the comprehensive data sets containing their clinical history combined with the genetic, blood biochemistry and cell count profiles, lifestyle data, drug and supplement use and other data types, because they do not see the value in this data and do not get tested regularly. On the other hand, the pharmaceutical and consumer companies alike are willing to pay substantial amounts for the large numbers of personal data records required to train their AI. These funds can be used to subsidize the regular testing by the patients, uncover the new uses for the various data types and develop sophisticated diagnostic and treatment tools.
"In the post neoclassical world, healthy productive longevity will be the new driver of economic growth. Creating an economy around human life data and returning the ownership and the control over life data back to the individual is one of the most important steps towards extending healthy productive longevity of the global population. It is also a very altruistic cause, which may help reduce the gap between the rich and the poor and allow the people from all walks of life and geographies to equally profit from their own data", said Alex Zhavoronkov, the founder of Insilico Medicine, Inc. 
###
For further information, images or interviews, please contact:
Contact: Qingsong Zhu, PhD
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions.
The company utilizes advances in genomics, big-data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company is pursuing internal drug discovery programs in cancer, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging.
Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. http://www.insilico.com